Skip to main content

Market Overview

Wedbush Maintains Outperform on Avanir Pharmaceuticals (AVNR)

Share:

Wedbush is out with its report today on Avanir Pharmaceuticals (NASDAQ: AVNR), maintaining Outperform.

In a note to clients, Wedbush writes, "AVNR reported Q2 NUEDEXTA revenues of $505 thousand and EPS of ($0.12), vs. our estimate of $404 thousand, ($0.14) and the Street's ~0.9-1 million, ($0.11). We anticipate full fiscal year sales of NUEDEXTA of $12.6 million, and anticipate the company will end FY:2011 with $45 million in cash and has cash runway into 2013. We maintain our OUTPERFORM rating and our $13 price target. We derive our $13 price target by applying a 6x multiple to 2015 revenues of ~$670 million, discounted by 25% annually."

Shares of AVNR closed Monday at $4.12, up 1.23% from Friday's close.

 

Related Articles (AVNR)

View Comments and Join the Discussion!

Posted-In: Avanir Pharmaceuticals WedbushAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com